Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 11.88% is 33% above its 5-year average of 8.93%, near the high end of its 5-year range (-100.72%–14.76%).
0.01% below its 12-month average of 11.88%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-07-04): 12.35%.
EBITDA MARGIN
11.88%
EBITDA MARGIN AVG TTM
11.88%
EBITDA MARGIN AVG 3Y
10.37%
EBITDA MARGIN AVG 5Y
8.93%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.01%
CURRENT VS 3Y AVG
+14.57%
CURRENT VS 5Y AVG
+33.08%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Aveanna Healthcare Holdings Inc.
Market Cap
$2.68B
EBITDA Margin
11.88%
TTM Avg
11.88%
3Y Avg
10.37%
5Y Avg
8.93%
Market Cap
$2.68B
EBITDA Margin
11.52%
TTM Avg
13.31%
3Y Avg
15.86%
5Y Avg
16.56%
Market Cap
$2.70B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.70B
EBITDA Margin
17.42%
TTM Avg
19.36%
3Y Avg
20.74%
5Y Avg
18.34%
Market Cap
$2.71B
EBITDA Margin
-1067.75%
TTM Avg
-2196.34%
3Y Avg
-1532.38%
5Y Avg
-1148.77%
Market Cap
$2.60B
EBITDA Margin
-270.04%
TTM Avg
-444.88%
3Y Avg
-365.27%
5Y Avg
-89273.54%
Market Cap
$2.59B
EBITDA Margin
-1001.92%
TTM Avg
-694.29%
3Y Avg
-672.56%
5Y Avg
-672.56%
Market Cap
$2.58B
EBITDA Margin
2.08%
TTM Avg
1.74%
3Y Avg
1.01%
5Y Avg
-2.48%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aveanna Healthcare Holdings Inc. (AVAH) | $2.68B | 11.88% | 11.88% | 10.37% | 8.93% |
| Neogen Corporation (NEOG)vs › | $2.68B | 11.52% | 13.31% | 15.86% | 16.56% |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.70B | N/A | N/A | N/A | N/A |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.70B | 17.42% | 19.36% | 20.74% | 18.34% |
| Precigen, Inc. (PGEN)vs › | $2.71B | -1067.75% | -2196.34% | -1532.38% | -1148.77% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.60B | -270.04% | -444.88% | -365.27% | -89273.54% |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.59B | -1001.92% | -694.29% | -672.56% | -672.56% |
| Privia Health Group, Inc. (PRVA)vs › | $2.58B | 2.08% | 1.74% | 1.01% | -2.48% |
| AtriCure, Inc. (ATRC)vs › | $2.80B | 3.20% | -0.69% | -3.43% | -1.09% |
| TransMedics Group, Inc. (TMDX)vs › | $2.80B | 22.42% | 17.70% | -0.76% | -37.34% |
Gross Margin
31.9%
EBITDA Margin
11.9%
Operating Margin
11.1%
Net Margin
10.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-07-04 | 12.35% |
| 2026-04-04 | 12.90% |
| 2026-01-03 | 12.08% |
| 2025-09-27 | 10.19% |
| 2025-06-28 | 14.76% |
| 2025-03-29 | 10.51% |
| 2024-12-31 | 10.19% |
| 2024-09-28 | 8.13% |
| 2024-06-29 | 8.83% |
| 2024-03-30 | 6.52% |
| 2023-12-31 | 7.60% |
| 2023-09-30 | -14.45% |
| 2023-07-01 | 9.52% |
| 2023-04-01 | 4.65% |
| 2022-12-31 | -43.25% |
| 2022-10-01 | 3.17% |
| 2022-07-02 | -100.72% |
| 2022-04-02 | 5.28% |
| 2021-12-31 | -25.09% |
| 2021-10-02 | 6.16% |
| 2021-07-03 | 9.44% |
| 2021-04-03 | 8.80% |
| 2020-12-31 | 6.07% |
| 2020-09-30 | 5.53% |
| 2020-06-30 | -12.61% |
| 2020-03-31 | 7.09% |
